Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Blood. 2011 Dec 22;118(26):6845-8. doi: 10.1182/blood-2011-09-377804. Epub 2011 Nov 8.
IL-15 promotes activation and maintenance of natural killer (NK) and CD8(+) T effector memory (T(EM)) cells, making it a potential immunotherapeutic agent for the treatment of cancer and immunodeficiency states. Here we report the immunologic effects of 3 different IL-15 dosing strategies in Rhesus macaques. IL-15 at a dose of 20 μg/kg/d administered by continuous intravenous infusion for 10 days resulted in a massive (100-fold) expansion of CD8(+) T(EM) cells in the peripheral blood. In contrast, the administration of 20-40 μg/kg/d of IL-15 by subcutaneous injection resulted in a more modest (10-fold) expansion of CD8(+) T(EM) cells. NK expansion was similar in both the continuous intravenous and daily subcutaneous treatment groups. The observation that IL-15 administered by continuous intravenous infusion is able to induce markedly greater expansions of CD8(+) T(EM) cells than the same dose administered by other routes may have important implications for clinical development of this cytokine.
白细胞介素-15(IL-15)促进自然杀伤(NK)和 CD8+T 效应记忆(T(EM))细胞的激活和维持,使其成为治疗癌症和免疫缺陷状态的潜在免疫治疗剂。在这里,我们报告了在恒河猴中三种不同 IL-15 给药策略的免疫效应。20 μg/kg/d 的 IL-15 剂量通过连续静脉输注 10 天给药,导致外周血中 CD8+T(EM)细胞大量(100 倍)扩增。相比之下,皮下注射 20-40 μg/kg/d 的 IL-15 导致 CD8+T(EM)细胞适度(10 倍)扩增。连续静脉内和每日皮下治疗组的 NK 扩增相似。观察到连续静脉内给予 IL-15 比其他途径给予相同剂量能显著更大程度地扩增 CD8+T(EM)细胞,这可能对这种细胞因子的临床开发具有重要意义。